Aeropay | $20,000,000 | (May 17, 2024)
Bedrock Materials | $9,000,000 | (May 17, 2024)
OTPLESS | $3,500,000 | (May 17, 2024)
SURGE Therapeutics
United States
- Cambridge, MA
- 20/07/2023
- Series B
- $32,000,000
SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time.
Surgery is the standard of care for most patients with solid tumors, and we are working tirelessly to ensure that nobody grieves the loss of a loved one to preventable post-surgical cancer recurrence.
- Industry Biotechnology
- Website http://surgetx.com/
- LinkedIn https://www.linkedin.com/company/surge-therapeutics/
Related People
Michael GoldbergFounder
United States -
Cambridge, Massachusetts
SURGE has developed a technology platform that enables extended localized release of cancer immunotherapy in the context of surgical tumor resection. This approach dramatically improves the efficacy and safety of cancer immunotherapy relative to administration of the same compounds via traditional routes, whether systemically or locally.
While Michael had a successful career in academia (publishing in Cell, Nature, Science, Nature Biotechnology, and Science Translational Medicine), he felt an obligation to focus all of his time and energy on clinical translation of the most exciting therapeutic platform that he has ever seen. Surgery is standard of care for most cancer patients with solid tumors, and the deployment of immunotherapy in this context has the potential to enhance the standard of care.
ekko | $2,500,000 | (May 17, 2024)
Watershed Health | $13,600,000 | (May 17, 2024)
HEPHAISTOS-Pharma | $11,189,199 | (May 17, 2024)
Keyper | $4,000,000 | (May 17, 2024)
c/side | $1,700,000 | (May 17, 2024)
SINE Digital | $2,500,000 | (May 17, 2024)
Angel AI | $4,750,000 | (May 17, 2024)
InstaAstro | $2,300,000 | (May 17, 2024)
Fay | $25,000,000 | (May 16, 2024)